# Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Source: https://onco.cc/trials/nct06229041/  
OnCo record `nct06229041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Peking University Cancer Hospital & Institute, now recruiting.

## Summary

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) is a phase 3, randomised interventional study registered as NCT06229041 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 472 participants, started 2023-03-29 and due to reach its primary completion in 2027-10-01. Interventions recorded: Camrelizumab ＋Immunotherapy. Conditions listed: Rectal Cancer. Primary outcome: The PCR rate between total neoadjuvant treatment ±immunotherapy. Colorectal eligibility wording from the registry: "colorectal adenocarcinoma confirmed by pathology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06229041
- Phase: 3
- Setting: Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 472

## Sources

- ClinicalTrials.gov NCT06229041: https://clinicaltrials.gov/study/NCT06229041

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06229041.json